CD30 expression in peripheral T-cell lymphomas
Elena Sabattini,Marco Pizzi,Valentina Tabanelli,Pamela Baldin,Carlo Alberto Sagramoso Sacchetti,Claudio Agostinelli,Pier Luigi Zinzani,Stefano Pileri +7 more
Reads0
Chats0
TLDR
CD30 antigen is a trans-membrane glycoprotein belonging to the tumor necrosis factor receptor superfamily and exerts pleiotropic effects on cell growth and survival, which largely depend on the NF-κB pathway activation.Abstract:
CD30 antigen is a trans-membrane glycoprotein belonging to the tumor necrosis factor receptor superfamily.[1][1] Upon stimulation, CD30 exerts pleiotropic effects on cell growth and survival, which largely depend on the NF-κB pathway activation.[2][2] In normal or inflamed tissues, CD30 expressionread more
Citations
More filters
Journal ArticleDOI
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
Steven M. Horwitz,Owen A. O'Connor,Barbara Pro,Timothy M Illidge,Michelle A. Fanale,Ranjana H. Advani,Nancy L. Bartlett,Jacob Haaber Christensen,Franck Morschhauser,Eva Domingo-Domenech,Giuseppe Rossi,Won Seog Kim,Tatyana Feldman,Anne Lennard,David Belada,Árpád Illés,Kensei Tobinai,Kunihiro Tsukasaki,Su-Peng Yeh,Andrei R. Shustov,Andreas Hüttmann,Kerry J. Savage,Sam Yuen,Swaminathan Padmanabhan Iyer,Pier Luigi Zinzani,Zhaowei Hua,Meredith Little,Shangbang Rao,Joseph Woolery,Thomas Manley,Lorenz Trümper +30 more
TL;DR: Front-line treatment with A+CHP is superior to CHOP for patients with CD30-positive peripheral T-cell lymphomas as shown by a significant improvement in progression-free survival and overall survival with a manageable safety profile.
Journal ArticleDOI
Peripheral T-cell lymphoma, not otherwise specified
TL;DR: The IPI score, and its variant called PIT, remains the most effective prognostic factor, and patients with PTCL-NOS should be treated with anthracycline-containing chemotherapy, followed by radiotherapy in cases of stage I-II disease.
Journal ArticleDOI
Angioimmunoblastic T-cell lymphoma: the many faced lymphoma
Matthew A. Lunning,Julie M. Vose +1 more
TL;DR: Induction strategies continue to focus on increasing complete remission rates that allow more transplant-eligible patients to proceed toward consolidative high-dose therapy and autologous stem cell rescue with improving long-term survival.
Journal ArticleDOI
The Role of Activator Protein-1 (AP-1) Family Members in CD30-Positive Lymphomas
Ines Garces de los Fayos Alonso,Ines Garces de los Fayos Alonso,Huan-Chang Liang,Suzanne D. Turner,Sabine Lagger,Olaf Merkel,Lukas Kenner,Lukas Kenner +7 more
TL;DR: The impact of deregulated expression of AP-1 TFs in CD30-positive lymphomas including Classical Hodgkin Lymphoma and Anaplastic Large Cell Lymphomas is focused on.
Journal ArticleDOI
Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels.
Céline Bossard,Maria Pamela Dobay,Marie Parrens,Laurence Lamant,Edoardo Missiaglia,Corinne Haioun,Antoine Martin,Bettina Fabiani,Richard Delarue,Olivier Tournilhac,Mauro Delorenzi,Mauro Delorenzi,Philippe Gaulard,Philippe Gaulard,Laurence de Leval +14 more
TL;DR: Investigation of the correlation between semiquantitative CD30 protein assessment by IHC and messenger RNA assessment by microarrays in a cohort of 376 noncutaneous PTCLs concludes that IHC is a valuable tool in clinical practice to assess CD30 expression in P TCLs.
References
More filters
Journal ArticleDOI
The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells.
Harald Stein,D Y Mason,Johannes Gerdes,N O'Connor,J. S. Wainscoat,Gorm Pallesen,K C Gatter,B Falini,Georges Delsol,Hilmar Lemke,R Schwarting,Karl Lennert +11 more
TL;DR: Results obtained indicate that Ki-1 antigen is an inducible lymphoid-associated molecule that identifies a group of hitherto poorly characterized normal and neoplastic large lymphoid cells in Hodgkin's disease and Disorders in which only a minority of cells express Ki- 1 antigen probably represent lesions in whichonly some of the abnormal cells have transformed into an "activation state.
Journal ArticleDOI
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
Anas Younes,Nancy L. Bartlett,John P. Leonard,Dana A. Kennedy,Carmel M. Lynch,Eric L. Sievers,Andres Forero-Torres +6 more
TL;DR: Brentuximab vedotin induced durable objective responses and resulted in tumor regression for most patients with relapsed or refractory CD30-positive lymphomas in this phase 1 study.
Journal ArticleDOI
Antigen retrieval techniques in immunohistochemistry: comparison of different methods.
Stefano Pileri,Giovanna Roncador,Claudio Ceccarelli,Milena Piccioli,Aspasia Briskomatis,Elena Sabattini,Stefano Ascani,Donatella Santini,Pier Paolo Piccaluga,Ornella Leone,Stefania Damiani,Cesarina Ercolessi,Federica Sandri,F. Pieri,Lorenzo Leoncini,Brunangelo Falini +15 more
TL;DR: Routine sections of normal and pathological samples fixed in 10 per cent buffered formalin or B5, including EDTA‐decalcified bone‐marrow biopsies, were tested with 61 antibodies following heating, and EDTA appeared to be superior in terms of both staining intensity and the number of marked cells.
Journal ArticleDOI
Marker Expression in Peripheral T-Cell Lymphoma: A Proposed Clinical-Pathologic Prognostic Score
Philip Went,Claudio Agostinelli,Andrea Gallamini,Pier Paolo Piccaluga,Stefano Ascani,Elena Sabattini,Francesco Bacci,Brunangelo Falini,Teresio Motta,Marco Paulli,Tullio Artusi,Milena Piccioli,Pier Luigi Zinzani,Stefano Pileri +13 more
TL;DR: A retrospective analysis shows a wide range of protein expression in PTCLs and proposes a new prognostic index, which represents one of the first examples of mixed score (including patient- and tumor-specific factors) applied to malignant lymphomas and may be the basis for future prospective therapeutic trials.
Journal ArticleDOI
Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin
Brunangelo Falini,L. Flenghi,Franco Aversa,G. Barbabietola,M. F. Martelli,P Comeli,Pl Tazzari,M. k. Broe,Harald Stein,Horst Dürkop,Giovanni Pizzolo,Andrea Bolognesi,F. Stirpe,Elena Sabattini,Stefano Pileri +14 more
TL;DR: In Hodgkin's disease, Hodgkin and Reed-Sternberg cells consistently express the antigen CD30 and the possible therapeutic role of an immunotoxin prepared by covalent linking of an anti-CD30 monoclonal antibody to saporin, a type-1 ribosome-inactivating protein is investigated.
Related Papers (5)
International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes.
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
Steven M. Horwitz,Owen A. O'Connor,Barbara Pro,Timothy M Illidge,Michelle A. Fanale,Ranjana H. Advani,Nancy L. Bartlett,Jacob Haaber Christensen,Franck Morschhauser,Eva Domingo-Domenech,Giuseppe Rossi,Won Seog Kim,Tatyana Feldman,Anne Lennard,David Belada,Árpád Illés,Kensei Tobinai,Kunihiro Tsukasaki,Su-Peng Yeh,Andrei R. Shustov,Andreas Hüttmann,Kerry J. Savage,Sam Yuen,Swaminathan Padmanabhan Iyer,Pier Luigi Zinzani,Zhaowei Hua,Meredith Little,Shangbang Rao,Joseph Woolery,Thomas Manley,Lorenz Trümper +30 more